- Home
- ATR vs ABVX Comparison
ATR vs ABVX Comparison
Compare ATR & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATR | ABVX |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Plastic Products | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 9.6B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATR | ABVX |
|---|---|---|
| Price | $117.55 | $129.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $167.50 | $112.83 |
| AVG Volume (30 Days) | 553.5K | ★ 1.6M |
| Earning Date | 10-30-2025 | 08-11-2025 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | ★ 24.99 | N/A |
| EPS | ★ 6.23 | N/A |
| Revenue | ★ $3,662,533,000.00 | $7,073,400.00 |
| Revenue This Year | $3.99 | $6.80 |
| Revenue Next Year | $3.38 | N/A |
| P/E Ratio | $18.81 | ★ N/A |
| Revenue Growth | ★ 2.50 | N/A |
| 52 Week Low | $103.23 | $4.77 |
| 52 Week High | $174.10 | $138.49 |
Technical Indicators
Market Signals| Indicator | ATR | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 67.17 |
| Support Level | $120.80 | $107.06 |
| Resistance Level | $124.26 | $130.25 |
| Average True Range (ATR) | 2.62 | 7.01 |
| MACD | -0.18 | -0.32 |
| Stochastic Oscillator | 21.83 | 70.18 |
Price Performance
Historical ComparisonAbout ATR AptarGroup Inc.
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. With the bulk of its annual net sales coming from Europe (49% of sales) and the United States (32%), Aptar aims to increase its presence in Asia (11%) and Latin America (8%). It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.